Caseware UK (AP4) 2023.0.135 2023.0.135 2024-10-312024-10-31false2023-11-01falseTraining services and selling books on neonatal care33falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 12967567 2023-11-01 2024-10-31 12967567 2022-11-01 2023-10-31 12967567 2024-10-31 12967567 2023-10-31 12967567 c:Director1 2023-11-01 2024-10-31 12967567 d:OfficeEquipment 2023-11-01 2024-10-31 12967567 d:OfficeEquipment 2024-10-31 12967567 d:OfficeEquipment 2023-10-31 12967567 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-11-01 2024-10-31 12967567 d:ComputerEquipment 2023-11-01 2024-10-31 12967567 d:ComputerEquipment 2024-10-31 12967567 d:ComputerEquipment 2023-10-31 12967567 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-11-01 2024-10-31 12967567 d:OwnedOrFreeholdAssets 2023-11-01 2024-10-31 12967567 d:ComputerSoftware 2024-10-31 12967567 d:ComputerSoftware 2023-10-31 12967567 d:CurrentFinancialInstruments 2024-10-31 12967567 d:CurrentFinancialInstruments 2023-10-31 12967567 d:CurrentFinancialInstruments d:WithinOneYear 2024-10-31 12967567 d:CurrentFinancialInstruments d:WithinOneYear 2023-10-31 12967567 d:ShareCapital 2024-10-31 12967567 d:ShareCapital 2023-10-31 12967567 d:RevaluationReserve 2024-10-31 12967567 d:RevaluationReserve 2023-10-31 12967567 d:RetainedEarningsAccumulatedLosses 2024-10-31 12967567 d:RetainedEarningsAccumulatedLosses 2023-10-31 12967567 d:AcceleratedTaxDepreciationDeferredTax 2024-10-31 12967567 d:AcceleratedTaxDepreciationDeferredTax 2023-10-31 12967567 c:FRS102 2023-11-01 2024-10-31 12967567 c:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 12967567 c:FullAccounts 2023-11-01 2024-10-31 12967567 c:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 12967567 d:ComputerSoftware d:ExternallyAcquiredIntangibleAssets 2023-11-01 2024-10-31 12967567 2 2023-11-01 2024-10-31 12967567 5 2023-11-01 2024-10-31 12967567 6 2023-11-01 2024-10-31 12967567 d:ComputerSoftware d:OwnedIntangibleAssets 2023-11-01 2024-10-31 12967567 e:PoundSterling 2023-11-01 2024-10-31 iso4217:GBP xbrli:pure

Registered number: 12967567









FINE NEONATAL UK LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 OCTOBER 2024

 
FINE NEONATAL UK LTD
REGISTERED NUMBER: 12967567

BALANCE SHEET
AS AT 31 OCTOBER 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 4 
5,093
5,121

Tangible assets
 5 
3,242
4,665

Investments
  
159,698
49,000

  
168,033
58,786

Current assets
  

Stocks
  
4,381
7,052

Debtors: amounts falling due within one year
 7 
25,996
10,382

Cash at bank and in hand
 8 
106,102
160,195

  
136,479
177,629

Creditors: amounts falling due within one year
 9 
(36,026)
(31,211)

Net current assets
  
 
 
100,453
 
 
146,418

Total assets less current liabilities
  
268,486
205,204

Provisions for liabilities
  

Deferred tax
 10 
(3,712)
(1,166)

  
 
 
(3,712)
 
 
(1,166)

Net assets
  
264,774
204,038


Capital and reserves
  

Called up share capital 
  
100
100

Revaluation reserve
  
8,703
-

Profit and loss account
  
255,971
203,938

  
264,774
204,038


Page 1

 
FINE NEONATAL UK LTD
REGISTERED NUMBER: 12967567
    
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 



I M Warren
Director

Date: 7 April 2025

The notes on pages 3 to 11 form part of these financial statements.

Page 2

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

1.


General information

FINE Neonatal UK Ltd is a company incorporated in England & Wales under the Companies Act 2006. The address of the registered office is given on the Company Information page. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 3

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

2.Accounting policies (continued)

 
2.4

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.6

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

2.Accounting policies (continued)


2.7
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
20%
Straight-line
Computer equipment
-
33%
Straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Revaluation of tangible fixed assets

Individual freehold and leasehold properties are carried at current year value at fair value at the date of the revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. Revaluations are undertaken with sufficient regularity to ensure the carrying amount does not differ materially from that which would be determined using fair value at the balance sheet date.
Fair values are determined from market based evidence normally undertaken by professionally qualified valuers.

Revaluation gains and losses are recognised in other comprehensive income unless losses exceed the previously recognised gains or reflect a clear consumption of economic benefits, in which case the excess losses are recognised in profit or loss.

 
2.9

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Profit and Loss Account for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

Page 5

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

2.Accounting policies (continued)

 
2.10

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.14

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.15

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees




The average monthly number of employees, including directors, during the year was 3 (2023 - 3).

Page 6

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

4.


Intangible assets




Website

£



Cost


At 1 November 2023
7,209


Additions
1,068



At 31 October 2024

8,277



Amortisation


At 1 November 2023
2,088


Charge for the year on owned assets
1,096



At 31 October 2024

3,184



Net book value



At 31 October 2024
5,093



At 31 October 2023
5,121



Page 7

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

5.


Tangible fixed assets





Office equipment
Computer equipment
Total

£
£
£



Cost or valuation


At 1 November 2023
2,507
6,738
9,245


Additions
-
673
673



At 31 October 2024

2,507
7,411
9,918



Depreciation


At 1 November 2023
125
4,455
4,580


Charge for the year on owned assets
502
1,594
2,096



At 31 October 2024

627
6,049
6,676



Net book value



At 31 October 2024
1,880
1,362
3,242



At 31 October 2023
2,382
2,283
4,665

Page 8

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

6.


Fixed asset investments





Listed investments

£



Cost or valuation


At 1 November 2023
49,000


Additions
99,094


Revaluations
11,604



At 31 October 2024
159,698




Page 9

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

7.


Debtors

2024
2023
£
£


Trade debtors
24,734
10,382

Prepayments and accrued income
1,262
-

25,996
10,382



8.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
106,102
160,195

106,102
160,195



9.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
19,452
16,407

Other taxation and social security
11,049
9,779

Other creditors
500
-

Accruals and deferred income
5,025
5,025

36,026
31,211



10.


Deferred taxation




2024


£






At beginning of year
(1,166)


Charged to profit or loss
(2,546)



At end of year
(3,712)

Page 10

 
FINE NEONATAL UK LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024
 
10.Deferred taxation (continued)

2024
2023
£
£


Accelerated capital allowances
(3,712)
(1,166)

(3,712)
(1,166)


11.


Related party transactions

In others creditors there is a Director's loan of £500 (2023: £nil) provided to the company.
Interest of 0% is paid on this loan and it is repayable on demand.

 
Page 11